Autopsy report · NCT03310593

Cannabidiol as an Adjunctive Treatment for Bipolar Depression

“It was interrupted due to the coronavirus pandemic outbreak.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 2 years 5 months before it stopped.
• 36 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Hospital de Clinicas de Porto Alegre

Sponsor type

University, hospital or other

Conditions

Bipolar Disorder; Bipolar Depression; Bipolar Affective Disorder

Interventions

Cannabidiol; Placebo

Participants

36

Sites

1

Countries

Brazil

Trials that died the same way

• n-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy
  “Due to the COVID-19 pandemic, enrollment was interrupted. The intervention pills expired and unable to obtain more.” (61% match in meaning)
• Combined Effect of tDCS and Motor or Cognitive Activity in Patients With Alzheimer's Disease
  “The study was interrupted before reaching the planned sample size due to the SARS-CoV-2 pandemic.” (60% match in meaning)
• FMT for MDRO Colonization After Infection in Renal Transplant Recipients
  “This study was paused and was not resumed due to the COVID-19 pandemic.” (60% match in meaning)
• A Comparison of Stryker's Tritanium Posterior Lumbar Cage and PEEK Implant
  “Due to COVID-19 disruption” (59% match in meaning)
• Effect of Artificial Tears on Biometry
  “Stopped due to COVID-19.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.